Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives

Semwal, Prabhakar; Painuli, Sakshi; Abu-Izneid, Tareq; Rauf, Abdur; Sharma, Anshu; Daştan, Sevgi Durna; Kumar, Manoj; Alshehri, Mohammed M.; Taheri, Yasaman; Das, Rajib; Mitra, Saikat; Emran, Talha Bin; Sharifi‐Rad, Javad; Calina, Daniela; Cho, William C.

doi:10.1155/2022/1035441

Cited by 85 publications

(59 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, this allows effective intervention with tailored treatments by blocking certain biological processes of tumor cells which allows effective interference with targeted therapeutics by impeding specific biological pathways of tumorinfected cells [9,11]. Cancer is frequently associated with the number of mutations that interrupt the key signaling pathways [12][13][14]. Cellular signaling pathways are organized as modular networks that communicate in real-time [15,16].…”

Section: Introductionmentioning

confidence: 99%

Targeting Ras-ERK cascade by bioactive natural products for potential treatment of cancer: an updated overview

Ali

Akter

Ramproshad³

et al. 2022

Cancer Cell Int

Self Cite

View full text Add to dashboard Cite

MAPK (mitogen-activated protein kinase) or ERK (extracellular-signal-regulated kinase) pathway is an important link in the transition from extracellular signals to intracellular responses. Because of genetic and epigenetic changes, signaling cascades are altered in a variety of diseases, including cancer. Extant studies on the homeostatic and pathologic behavior of MAPK signaling have been conducted; however, much remains to be explored in preclinical and clinical research in terms of regulation and action models. MAPK has implications for cancer therapy response, more specifically in response to experimental MAPK suppression, compensatory mechanisms are activated. The current study investigates MAPK as a very complex cell signaling pathway that plays roles in cancer treatment response, cellular normal conduit maintenance, and compensatory pathway activation. Most MAPK inhibitors, unfortunately, cause resistance by activating compensatory feedback loops in tumor cells and tumor microenvironment components. As a result, innovative combinatorial treatments for cancer management must be applied to limit the likelihood of alternate pathway initiation as a possibility for generating novel therapeutics based on incorporation in translational research. We summarize current knowledge about the implications of ERK (MAPK) in cancer, as well as bioactive products from plants, microbial organisms or marine organisms, as well as the correlation with their chemical structures, which modulate this pathway for the treatment of different types of cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting Ras-ERK cascade by bioactive natural products for potential treatment of cancer: an updated overview

Ali

Akter

Ramproshad³

et al. 2022

Cancer Cell Int

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cancer treatment has evolved rapidly over the last decade, toward a personalized approach [ 47 , 89 ]. Modern technologies today allow a molecular characterization that outlines a unique picture for each patient.…”

Section: Therapeutic Perspectives Limitations and Challenges Associat...mentioning

confidence: 99%

Recent advances and limitations of mTOR inhibitors in the treatment of cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

The PI3K-Akt-mechanistic (formerly mammalian) target of the rapamycin (mTOR) signaling pathway is important in a variety of biological activities, including cellular proliferation, survival, metabolism, autophagy, and immunity. Abnormal PI3K-Akt-mTOR signalling activation can promote transformation by creating a cellular environment conducive to it. Deregulation of such a system in terms of genetic mutations and amplification has been related to several human cancers. Consequently, mTOR has been recognized as a key target for the treatment of cancer, especially for treating cancers with elevated mTOR signaling due to genetic or metabolic disorders. In vitro and in vivo, rapamycin which is an immunosuppressant agent actively suppresses the activity of mTOR and reduces cancer cell growth. As a result, various sirolimus-derived compounds have now been established as therapies for cancer, and now these medications are being investigated in clinical studies. In this updated review, we discuss the usage of sirolimus-derived compounds and other drugs in several preclinical or clinical studies as well as explain some of the challenges involved in targeting mTOR for treating various human cancers.

show abstract

“…The effectiveness of treatment depends on the correct administration, early detection, accurate diagnosis of cancer and compliance with standards of care [ 49 , 50 ]. Chemotherapy has severe side effects; therefore, natural remedies based on bioactive cytotoxic compounds are a valuable aid in cancer prophylaxis, but also a complementary alternative medicine (CAM) to various forms of cancer [ 51 , 52 , 53 ]. Cancer patients in the UK reported the use of apricot-derived products in CAM [ 54 , 55 ].…”

Section: Anticancer Activities: Underlying Multi-targets Mechanismsmentioning

confidence: 99%

Anticancer Potential and Other Pharmacological Properties of Prunus armeniaca L.: An Updated Overview

Kitić

Miladinović

Randjelović

et al. 2022

Plants

Self Cite

View full text Add to dashboard Cite

Prunus armeniaca L. (Rosaceae)-syn. Amygdalus armeniaca (L.) Dumort., Armeniaca armeniaca (L.) Huth, Armeniaca vulgaris Lam is commonly known as the apricot tree. The plant is thought to originate from the northern, north-western, and north-eastern provinces of China, although some data show that it may also come from Korea or Japan. The apricot fruit is used medicinally to treat a variety of ailments, including use as an antipyretic, antiseptic, anti-inflammatory, emetic, and ophthalmic remedy. The Chinese and Korean pharmacopeias describe the apricot seed as an herbal medicinal product. Various parts of the apricot plant are used worldwide for their anticancer properties, either as a primary remedy in traditional medicine or as a complementary or alternative medicine. The purpose of this review was to provide comprehensive and up-to-date information on ethnobotanical data, bioactive phytochemicals, anticancer potential, pharmacological applications, and toxicology of the genus Prunus armeniaca, thus providing new perspectives on future research directions. Included data were obtained from online databases such as PubMed/Medline, Google Scholar, Science direct, and Wiley Online Library. Multiple anticancer mechanisms have been identified in in vitro and in vivo studies, the most important mechanisms being apoptosis, antiproliferation, and cytotoxicity. The anticancer properties are probably mediated by the contained bioactive compounds, which can activate various anticancer mechanisms and signaling pathways such as tumor suppressor proteins that reduce the proliferation of tumor cells. Other pharmacological properties resulting from the analysis of experimental studies include neuroprotective, cardioprotective, antioxidant, immunostimulatory, antihyperlipidemic, antibacterial, and antifungal effects. In addition, data were provided on the toxicity of amygdalin, a compound found in apricot kernel seeds, which limits the long-term use of complementary/alternative products derived from P. armeniaca. This updated review showed that bioactive compounds derived from P. armeniaca are promising compounds for future research due to their important pharmacological properties, especially anticancer. A detailed analysis of the chemical structure of these compounds and their cytotoxicity should be carried out in future research. In addition, translational pharmacological studies are required for the correct determination of pharmacologically active doses in humans.

show abstract

Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives

Cited by 85 publications

References 159 publications

Targeting Ras-ERK cascade by bioactive natural products for potential treatment of cancer: an updated overview

Targeting Ras-ERK cascade by bioactive natural products for potential treatment of cancer: an updated overview

Recent advances and limitations of mTOR inhibitors in the treatment of cancer

Anticancer Potential and Other Pharmacological Properties of Prunus armeniaca L.: An Updated Overview

Contact Info

Product

Resources

About